Skip to: Content
Skip to: Site Navigation
Skip to: Search
SATURDAY, NOVEMBER 21, 2009
| Subscribe to Newser's RSS feeds RSS | Follow Newser on Twitter Twitter

NEWS ABOUT: GlaxoSmithKline

GlaxoSmithKline stories: 23 news summaries

1 - 20 of 23 Stories | 1 2 Next >>

Switch to grid view »

Anti-Smoking Chantix, Zyban Pose Suicide Risk: FDA

Smokers with mental illnesses should avoid them, agency says

Jul 1, 09 4:59 PM CDT
(Newser) - The Food and Drug Administration is warning smokers about serious mental-illness risks of two smoking-cessation drugs, as reported suicides among their users increase. Chantix and Zyban must now carry the agency’s strongest warning label, the New York Times reports. The FDA isn’t trying to scare patients, an official... More »

MORE ABOUT:
FDA • pharmaceutical companies • GlaxoSmithKline • Pfizer • smoking cessation • Chantix • women's issues • Zyban

Swiss Pharma Won't Donate Swine Flu Vaccine to Poor

Novartis defies WHO calls to give free doses to poor


Jun 15, 09 4:58 AM CDT
(Newser) - Swiss pharma giant Novartis is defying the World Health Organization by refusing to donate swine flu vaccines to the world's poor, despite the designation of H1N1 as the first pandemic in 40 years, reports the Financial Times. Last week the WHO's director general called on drug companies to show "... More »

MORE ABOUT:
pharmaceutical companies • drug companies • GlaxoSmithKline • Novartis • World Health Organization • flu shot • Tamiflu • flu medications • pharmaceutical industry • pandemic • swine flu

MARKETS

 Pharma Pushes Dow Down 83 

Sandisk gains after earnings beating expectations

Apr 22, 09 3:29 PM CDT
(Newser) - Stocks were mixed today as pharmaceuticals declined but tech saw gains, the Wall Street Journal reports. GlaxoSmithKline reported a 13% drop in first-quarter earnings; GSK, Merck and Pfizer shares dropped. Yahoo and Sandisk were up despite posting quarterly losses. The Dow fell 82.99 to close at 7,886.57.... More »

MORE ABOUT:
Yahoo • Dow Jones • GlaxoSmithKline • Nasdaq • SanDisk • S&P 500

Glaxo to Cut Drug Prices
in Developing World

No. 2 pharma firm will open 'patent pool' to outside scientists

Feb 14, 09 11:25 AM CST
(Newser) - GlaxoSmithKline’s new boss has proposed a radical rethinking of big pharma in developing countries: He plans to cut prices, offer portions of profits to hospitals, and loosen his firm’s grip on patents that keep prices up, the Guardian reports. “I think it's absolutely the kind of thing... More »

MORE ABOUT:
drug companies • GlaxoSmithKline • price • developing countries • pharmaceutical industry • patent

 Watershed Vaccine 
 May End Malaria Toll 

If trials work as expected, shots could save millions of children

Dec 9, 08 1:45 AM CST
(Newser) - Scientists have developed a promising vaccine against malaria, a devastating disease that kills a milion people a year, most of them young children. Trials of the breakthrough vaccine enter the final phase next year and it could be widely available by 2012, reports the Los Angeles Times. Successful trials have... More »

MORE ABOUT:
Kenya • medical breakthrough • malaria • Ethiopia • GlaxoSmithKline • Tanzania • vaccine • mosquito • Zambia • World Health Organization • Bill and Melinda Gates Foundation • Rwanda • RTS,S • PATH Malaria Vaccine Initiative

Ailing Biotech Firms Need
Shot in the Arm

Flatlining economy threatens breakthrough medical research

Nov 21, 08 1:05 PM CST
(Newser) - For the first time in years, the biotech industry is in desperate need of a lifeline, Bloomberg reports, as the economic crisis threatens to shove companies into bankruptcy and derail the development of potentially life-saving drugs. “I’m looking down the barrel of a gun,” admitted one CEO.... More »

MORE ABOUT:
Wall Street • investors • pharmaceutical companies • GlaxoSmithKline • stocks • biotechnology • Parkinson's disease • IPO • multiple sclerosis • biotech companies • Alzheimer's Disease • financial crisis

ANALYSIS

Big Pharma Seeks Big Profits in Developing Nations

Drug Makers See Future in New Markets

Nov 15, 08 2:47 AM CST
(Newser) - The pharmaceutical industry is turning away from the US shores that helped fill its pockets and toward the developing world, the Economist reports. Massive growth has made markets like India and China too attractive to ignore, despite lower income levels and weaker patent laws. And many companies fear Barack Obama's... More »

MORE ABOUT:
China • India • pharmaceutical companies • Medicare • GlaxoSmithKline • Pfizer • emerging markets • pharmaceutical industry

Serious Side Effects
Linked to Avandia, Fosamax 

Heart trouble, brittle bones tied to drugs

Apr 29, 08 2:57 AM CDT
(Newser) - Two new studies have linked the popular prescription drugs Fosamax and Avandia to serious side effects, Reuters reports. Fosamax, prescribed for osteoporosis, has been tied to a type of abnormal heartbeat that can cause dizziness and fatigue. Another study links Avandia, used to treat diabetes, to a double or even... More »

MORE ABOUT:
diabetes • Merck • GlaxoSmithKline • Avandia • osteoporosis • Fosamax • Food and Drug Administration • Dr. Jane Cauley

Antidepressants Mostly Useless, Study Finds

Prozac and others make a difference only  in most extreme cases

Feb 26, 08 7:41 AM CST
(Newser) - Big Pharma swallowed a bitter pill yesterday as Prozac and other antidepressants were found in a UK study to be largely ineffectual in all but the most extreme cases of depression. The meta-analysis of 47 clinical trials submitted to the FDA with licensing applications for six popular antidepressants concluded that... More »

MORE ABOUT:
medical breakthrough • depression • antidepressant • GlaxoSmithKline • prescription drugs • therapy • Eli Lilly • Prozac • Wyeth • pharmaceutical industry

Prices Jump for Top Drugs

Drug giants collect now against expected future losses

Feb 21, 08 4:45 AM CST
(Newser) - Drug companies have slapped a series of huge price hikes on some prescription drugs ahead of drug patent expirations, the Wall Street Journal reports. GlaxoSmithKline has raised the price of antidepressant Wellbutrin 44.5%, while Sanofi-Aventis hiked Ambien's price 70%. Wholesale prices for the top 50 drugs increased an average... More »

MORE ABOUT:
Barack Obama • Hillary Clinton • John McCain • antidepressant • drug companies • GlaxoSmithKline • Pfizer • health insurance premiums • price increases • health care reform • Centers for Medicare and Medicaid Services • Lipitor • pharmaceutical industry • co-pays • Ambien • Wellbutrin • Adderall XR • Sanofi-Aventis • Shire • patent expiration

Puerto Rican Drug Plants Shipped Tainted Pills: FDA

Quality control a problem at factories producing US' top-selling drugs

Feb 6, 08 1:38 PM CST
(Newser) - The Caribbean island that produces 13 of the 20 best-selling drugs in the US has sold tainted pills and is struggling with quality control at its pharmaceutical plants, AP reports.  FDA inspections of 13 Puerto Rican plants between 2003 and 2007 revealed problems such as machinery pins left in... More »

MORE ABOUT:
FDA • GlaxoSmithKline • Puerto Rico • pharmaceutical • Wyeth

Beefed-Up R&D Slows Drug Approval

Just 19 new meds cleared FDA in 2007

Jan 8, 08 5:45 PM CST
(Newser) - The FDA approved only 19 new drugs in 2007, the lowest total in 24 years. Bloomberg takes a look at the reasons. Some drug companies accuse the FDA of setting the bar higher for drug approvals, a charge the agency denies. Many, however, say the issue lies with big pharma... More »

MORE ABOUT:
FDA • drug safety • GlaxoSmithKline • Viviant • Tykerb • Novartis AG • Tasigna

Big Pharma Faces Big Plunge

Profits will drop as patents expire, and chemical-based therapies are eclipsed by biotech

Dec 6, 07 4:50 AM CST
(Newser) - Patent protections on some of the pharmaceutical industry's best-selling drugs, like Lipitor, Plavix and Singulair, are due to expire in the next several years, and drug manufacturers have little in the pipeline to replace them. The drug companies will lose billions—as much as half their combined revenue—to generic... More »

MORE ABOUT:
Merck • pharmaceutical companies • GlaxoSmithKline • Pfizer • Eli Lilly • Zocor • Lipitor • Plavix • pharmaceutical industry • Zyprexa • Fosamax • Singulair • Cozaar • torcetrapib • drug manufacturer

Tamiflu Will Carry Stronger Warning Labels

Maker will beef up language on possible psychiatric side effects

Nov 28, 07 4:51 PM CST
(Newser) - The maker of flu drug Tamiflu said today it will accept recommendations by a government panel that it revise printed warnings about the medication's side effects. Labels already warn of possible psychiatric reactions, but the panel recommended noting that some people have died, the AP reports. Drugmaker Roche says flu... More »

MORE ABOUT:
FDA • GlaxoSmithKline • Tamiflu • Relenza • flu medications • Roche

Diabetes Drug Given Strictest Warning Label

FDA's 'black box' adds risk of heart attack to concerns on Avandia

Nov 14, 07 3:20 PM CST
(Newser) - The FDA has applied its harshest warning to the diabetes drug Avandia, declaring the product potentially increases risk of heart attacks. Now marked with a “black box” warning, GlaxoSmithKline’s drug will stay on the market pending a continuing “safety assessment,” the Wall Street Journal reports; FDA... More »

MORE ABOUT:
FDA • diabetes • black box • GlaxoSmithKline • Avandia • Actos

Court Blocks New Patent Rules

Judge grants injunction for drug giant GlaxoSmithKline

Oct 31, 07 10:40 PM CDT
(Newser) - A Federal judge has blocked the US Patent and Trademark Office from implementing tough new patent rules with a temporary injunction in a suit brought by GlaxoSmithKline. The Wall Street Journal reports the new rules would have limited the number of times patent holders may make minor changes to existing... More »

MORE ABOUT:
technology • intellectual property • GlaxoSmithKline • Patent and Trademark Office • continuances • patent application process • pharmaceutical industry

FDA Panel Votes to Keep Avandia on Shelves

Controversial diabetes drug still faces heart-attack link

Jul 30, 07 5:38 PM CDT
(Newser) - An FDA panel said today that GlaxoSmithKline's diabetes drug Avandia should remain in drugstores, despite earlier evidence the pill ups heart failure risks. Glaxo has defended its drug, countering that the risks associated with the popular Avandia are the same as those of other diabetes drugs. More »

MORE ABOUT:
FDA • health • drugs • diabetes • GlaxoSmithKline • Avandia • safety • heart failure

Dow Sinks Further on Credit Jitters

GDP report, earnings, can't stave off 208.10
point slide

Jul 27, 07 4:10 PM CDT
(Newser) - Stocks tumbled more than 200 points for the second day in a row, on fears that small-cap securities might be especially hard hit by a possible collapse in certain financial services. The Dow was down 208.10 to 13265.47, despite a report that the GDP grew faster this quarter... More »

MORE ABOUT:
Wall Street • FDA • GlaxoSmithKline • Avandia • stocks • Nasdaq • GDP • S&P 500

Controversy Rages Over Diabetes Drug's Heart Risks

FDA official says superiors ordered her to back off serious warning

Jun 6, 07 12:16 PM CDT
(Newser) - Troubling questions about the diabetes drug Avandia persisted yesterday as an FDA official revealed that she was barred from recommending a critical warning about the medication, the Times reports. In the run-up to congressional hearings that began today, manufacturer GlaxoSmithKline rushed to disseminate interim clinical findings in hopes of blunting... More »

MORE ABOUT:
medicine • FDA • health • diabetes • GlaxoSmithKline • Avandia • heart • heart attack

Glaxo Stems Stock Slide
Over Avandia

Medical chief rebuts findings on heart risks; claims comparable to other drugs

May 31, 07 6:44 AM CDT
(Newser) - Glaxo shares pulled out of a tailspin after the pharma giant defended its second biggest selling drug, Avandia, against claims that it triggers heart attacks.  A sharply worded letter from the company's chief medical officer on the website of medical journal The Lancet pointed out that the increased incidence... More »

MORE ABOUT:
medicine • drugs • diabetes • GlaxoSmithKline • Avandia • pharma • heart attack

1 - 20 of 23 Stories | 1 2 Next >>


from our news partners